Completed PHASE3 INTERVENTIONAL NCT00489528

Growth Hormone in the Treatment of HIV-Associated Wasting

A Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Recombinant Human Growth Hormone (Serostim) in the Treatment of HIV-Associated Catabolism/Wasting

Sponsor: EMD Serono

Conditions HIV Infections HIV Wasting Syndrome

Interventions Somatropin; Recombinant human growth hormone (r hGH)

Updated 5 times since 2017 Last updated: Oct 21, 2013 Started: Jul 31, 1997 Completion: Mar 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates HIV Infections and HIV Wasting Syndrome and is currently completed. EMD Serono leads this study, which shows 5 recorded versions since 1997 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

EMD Serono

Data source: EMD Serono

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.